Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd is rated Buy by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 June 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

With every major technical indicator aligned to the upside, Sudarshan Pharma Industries Ltd surged to a fresh 52-week high of Rs 36.25 on 27 Jun 2026, marking a significant milestone in its price momentum journey.

Surging to a fresh 52-week high of Rs 36.25 on 27 Jun 2026, Sudarshan Pharma Industries Ltd has demonstrated robust price momentum, outpacing its specialty chemicals sector peers amid a broadly subdued market backdrop.

With a fresh 52-week high of Rs 35.9 reached on 26 Jun 2026, Sudarshan Pharma Industries Ltd has demonstrated notable price momentum, outperforming its specialty chemicals sector peers and the broader market. The stock’s steady climb, supported by a series of bullish technical indicators, underscores a robust upward trajectory that has carried it well above its 52-week low of Rs 18.5.

Sudarshan Pharma Industries Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. The micro-cap specialty chemicals company has demonstrated robust quarterly results, sustained long-term growth, and a bullish technical outlook, prompting this positive reassessment on 20 May 2026.

Sudarshan Pharma Industries Ltd has demonstrated a marked shift in price momentum, supported by a suite of bullish technical indicators. The micro-cap specialty chemicals company’s shares surged 5.00% on 21 May 2026, closing at ₹32.57, signalling renewed investor confidence and an upgrade in its technical outlook from mildly bullish to bullish.

Sudarshan Pharma Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Sudarshan Pharma Industries Ltd, a micro-cap player in the specialty chemicals sector, has recently experienced a nuanced shift in its technical momentum, prompting an upgrade in its Mojo Grade from Hold to Buy as of 5 May 2026. Despite a modest day decline of 2.39%, the stock’s underlying technical indicators reveal a complex but cautiously optimistic outlook for investors seeking exposure in this segment.

Sudarshan Pharma Industries Ltd has been upgraded from a Hold to a Buy rating following a marked improvement across key investment parameters including financial trends, valuation, quality metrics, and technical indicators. The company’s recent quarterly results and sustained market outperformance have underpinned this positive reassessment by analysts.

Sudarshan Pharma Industries Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators that suggest an improving outlook for this micro-cap specialty chemicals stock. Recent upgrades in its technical trend and a positive change in its Mojo Grade from Sell to Hold reflect growing investor confidence amid a broader market context.

Sudarshan Pharma Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with the latest insights into its performance and outlook.

Sudarshan Pharma Industries Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting cautious optimism for investors amid a micro-cap specialty chemicals sector backdrop.

Sudarshan Pharma Industries Ltd., a micro-cap specialty chemicals manufacturer with a market capitalisation of ₹710.00 crores, reported consolidated net profit of ₹10.73 crores for Q4 FY26, representing a remarkable sequential surge of 146.10% from ₹4.36 crores in Q3 FY26 and year-on-year growth of 44.80% from ₹7.41 crores in Q4 FY25. The stock traded at ₹30.26 on April 30, 2026, up 0.87% from the previous close, with shares hovering 14.01% below their 52-week high of ₹35.19 but substantially above the 52-week low of ₹18.50.

The 50-day moving average has crossed above the 200-day moving average for Sudarshan Pharma Industries Ltd, signalling a golden cross on 30 Apr 2026. Yet, the broader technical picture is nuanced, with monthly indicators showing mild bearishness and the stock’s recent price action reflecting a more complex momentum story.

Sudarshan Pharma Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sudarshan Pharma Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Oct 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.